Moderna reported $2.23B of revenue over the trailing twelve months, −28% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.23B (to Q2 2026). Net income: −$3.15B, trailing twelve months to Q2 2026. Free cash flow: −$1.24B, trailing twelve months to Q2 2026. Operating margin: −268%, trailing twelve months to Q2 2026.

MRNAModerna

Healthcare

$62.96+93% 1Y

$62.96

$22.3652 weeks$225.03

Latest close: a new 52-week highOct 9, 2026what changed →

MRNA as reported

Moderna reported $2.23B of revenue over the trailing twelve months, −28% on the year before. 10 reported series are charted on this page, each one as filed.

$2.23B

Revenue, trailing twelve months · to Q2 2026 · −28% against the twelve months before

Net income: −$3.15B
Net income · +8.5% year on year · trailing twelve months to Q2 2026
Free cash flow: −$1.24B
Free cash flow · −64% year on year · trailing twelve months to Q2 2026
Operating margin: −268%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for MRNA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.23B	−28%	Q2 2026
Net income	−$3.15B	+8.5%	Q2 2026
EPS	−$7.99	+6.1%	Q2 2026
Gross margin	0.83%	n/a	Q2 2026
Operating margin	−268%	n/a	Q2 2026
Net margin	−257%	n/a	Q2 2026
ROE	−39%	n/a	Q2 2026
ROA	−26%	n/a	Q2 2026
Free cash flow	−$1.24B	−64%	Q2 2026
P/E	17.6	n/a	Q2 2023 · 12 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.